Angiotensin-receptor blockade, cancer, and concerns

The Lancet Oncology

Volumn 11, Issue 9, 2010, Pages 818-819

  Böhm, Michael ^a   Laufs, Ulrich ^a   Pfreundschuh, Michael ^a  

^a Klinik fur Innere Medizin III   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; TELMISARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; DRUG EFFICACY; GASTROINTESTINAL TUMOR; HEART LEFT VENTRICLE FAILURE; HUMAN; LETTER; LUNG CANCER; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); META ANALYSIS (TOPIC); NEOPLASM;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; NEOPLASMS;

EID: 77956139244     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70162-5     Document Type: Letter

References (5)

1. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010, 11:627-636.
2. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358:1547-1559. for the ONTARGET investigators.
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302. The SOLVD investigators.
4. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691. The SOLVD investigators.
5. Sheperd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630. for the PROSPER study group.